Under the terms of this agreement, Asuragen will have the right to develop, manufacture and market products for the diagnosis, stratification and monitoring of patients with Acute Myeloid Leukemia (AML).
Rollie Carlson, president of Asuragen, said: “Adding NPM1 mutation testing to the treating physician’s testing arsenal will enable physicians and patients to make more informed choices in the treatment of AML. NPM1 testing complements Asuragen’s current leukemia products and we continue in our dedication to bring leading-edge leukemia diagnostic products such as NPM1 testing to the AML community.”